Cabozantinib added to erlotinib has antitumor activity in heavily pretreated patients with EGFR-positive non–small cell lung cancer (NSCLC) whose disease progressed on erlotinib alone, according to the results of a phase II trial presented at the 2014 ASCO Annual Meeting.
- A Network of Your PeersView more >>
Most Popular Right Now
Dr Richard Michaelson and Kimberly Blackwell, MD discuss their decision-making processes when treating patients with metastatic HR+/HER2- breast cancer. View Now